科伦药业今年以来股价涨11.42%，近5个交易日跌2.13%，近20日跌5.93%，近60日跌12.83%。 今年以来科伦药业已经2次登上龙虎榜，最近一次登上龙虎榜为4月30日，当日龙虎榜净买入3187.92万 元；买入总计2.54亿元 ，占总成交额比17.58%；卖出总计2.22亿元 ，占总成交额比15.37%。 11月24日，科伦药业盘中上涨2.03%，截至09:53，报32.65元/股，成交5481.10万元，换手率0.13%，总 市值521.76亿元。 资金流向方面，主力资金净流入246.52万元，特大单买入420.56万元，占比7.67%，卖出291.50万元，占 比5.32%；大单买入934.43万元，占比17.05%，卖出816.95万元，占比14.90%。 截至9月30日，科伦药业股东户数3.71万，较上期增加8.35%；人均流通股35200股，较上期减少7.70%。 2025年1月-9月，科伦药业实现营业收入132.77亿元，同比减少20.92%；归母净利润12.01亿元，同比减 少51.41%。 分红方面，科伦药业A股上市后累计派现68.98亿元。近三年，累计派现35.87亿元。 机构持仓 ...

截至9月30日，济民健康股东户数5.81万，较上期增加107.00%；人均流通股9035股，较上期减少 51.69%。2025年1月-9月，济民健康实现营业收入5.45亿元，同比减少20.21%；归母净利润-7715.04万 元，同比减少371.51%。 分红方面，济民健康A股上市后累计派现1.27亿元。近三年，累计派现1074.47万元。 责任编辑：小浪快报 融资方面，济民健康当日融资买入1161.17万元。当前融资余额2.24亿元，占流通市值的4.26%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，济民健康11月20日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量9000.00股，融券余额9.04万元，超过近一年90%分位水平，处于高位。 资料显示，济民健康管理股份有限公司位于浙江省台州市黄岩区北院路888号，成立日期1996年12月24 日，上市日期2015年2月17日，公司主营业务涉及医疗器械的研发、生产和销售,医疗服务,以及大输液产 品研发、生产和销售。主营业务收入构成为：医药制造52.07%，医疗服务46.01%，医药贸易1.54%，其 他 ...

Core Viewpoint - Kelong Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 12.54%, but recent declines over various trading periods indicate potential volatility in investor sentiment [1][2]. Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, representing a year-on-year decrease of 20.92%. The net profit attributable to shareholders was 1.201 billion yuan, down 51.41% year-on-year [2]. - Cumulatively, Kelong Pharmaceutical has distributed 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [3]. Stock Market Activity - As of November 12, Kelong Pharmaceutical's stock was trading at 32.98 yuan per share, with a market capitalization of 52.704 billion yuan. The stock experienced a net inflow of 7.8043 million yuan from main funds [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on April 30, where it recorded a net purchase of 31.8792 million yuan [1]. Shareholder Structure - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period. The average number of circulating shares per shareholder was 35,200, a decrease of 7.70% [2]. - The top ten circulating shareholders include various funds, with notable reductions in holdings for several institutional investors [3].

Group 1 - On November 11, Kelong Pharmaceutical experienced a decline of 1.79% with a trading volume of 312 million yuan. The financing buy amount for the day was 41.75 million yuan, while the financing repayment was 13.71 million yuan, resulting in a net financing buy of 28.04 million yuan. As of November 11, the total financing and securities lending balance was 916 million yuan [1] - The financing balance of Kelong Pharmaceutical was 912 million yuan, accounting for 1.77% of the circulating market value, which is above the 60th percentile level over the past year, indicating a relatively high position [1] - In terms of securities lending, Kelong Pharmaceutical repaid 2,100 shares and sold 5,800 shares on November 11, with a selling amount of 187,500 yuan. The remaining securities lending volume was 12,000 shares, with a balance of 3.88 million yuan, also exceeding the 60th percentile level over the past year [1] Group 2 - As of September 30, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% compared to the previous period. The average circulating shares per person decreased by 7.70% to 35,200 shares [2] - For the period from January to September 2025, Kelong Pharmaceutical reported operating revenue of 13.28 billion yuan, a year-on-year decrease of 20.92%. The net profit attributable to the parent company was 1.20 billion yuan, down 51.41% year-on-year [2] - Kelong Pharmaceutical has distributed a total of 6.90 billion yuan in dividends since its A-share listing, with 3.59 billion yuan distributed over the past three years [2] Group 3 - As of September 30, 2025, among the top ten circulating shareholders of Kelong Pharmaceutical, China Europe Medical Health Mixed A ranked as the third-largest shareholder with 40.06 million shares, a decrease of 2.54 million shares from the previous period. Hong Kong Central Clearing Limited was the fourth-largest shareholder with 34.73 million shares, down 5.26 million shares [3] - Other notable shareholders include Guangfa Multi-Factor Mixed Fund, which remained unchanged at 24.23 million shares, and ICBC Frontier Medical Stock A, which decreased by 7.01 million shares to 20 million shares [3] - The top ten shareholders also included Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, with holdings of 19.08 million shares and 14.04 million shares, respectively, both showing a decrease compared to the previous period [3]

Core Viewpoint - Kelong Pharmaceutical's stock has experienced a decline of 2.04% on November 11, with a current price of 32.25 CNY per share and a total market capitalization of 51.537 billion CNY. The company has seen a year-to-date stock price increase of 10.05%, but has faced recent declines over various trading periods [1][2]. Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion CNY, representing a year-on-year decrease of 20.92%. The net profit attributable to shareholders was 1.201 billion CNY, down 51.41% compared to the previous year [2]. - Cumulatively, Kelong Pharmaceutical has distributed a total of 6.898 billion CNY in dividends since its A-share listing, with 3.587 billion CNY distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period. The average number of circulating shares per shareholder decreased by 7.70% to 35,200 shares [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with several shareholders reducing their holdings compared to the previous period [3]. Stock Market Activity - Kelong Pharmaceutical has appeared on the stock market's "Dragon and Tiger List" twice this year, with the most recent instance on April 30, where it recorded a net purchase of 318.792 million CNY [1]. - The stock has seen a trading volume of 171 million CNY on the day of the report, with a turnover rate of 0.40% [1]. Business Overview - Kelong Pharmaceutical, established on May 29, 2002, and listed on June 3, 2010, is primarily engaged in the development, production, and sales of large-volume infusion products. The revenue composition includes 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concepts such as anesthesia, generic drugs, and innovative drugs [2].

Core Points - Jimin Health's stock price increased by 2.08% on November 11, reaching 10.33 CNY per share, with a market capitalization of 5.424 billion CNY [1] - The company has seen a year-to-date stock price increase of 52.14%, with a recent 5-day increase of 3.20% and a 60-day increase of 45.90% [1] - Jimin Health has appeared on the trading leaderboard 13 times this year, with the latest occurrence on September 11, where it recorded a net purchase of 66.0795 million CNY [1][2] Financial Performance - For the period from January to September 2025, Jimin Health reported a revenue of 545 million CNY, a year-on-year decrease of 20.21%, and a net profit of -77.1504 million CNY, a decrease of 371.51% [2] - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 10.7447 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, Jimin Health had 58,100 shareholders, an increase of 107% from the previous period, with an average of 9,035 circulating shares per shareholder, a decrease of 51.69% [2] Business Overview - Jimin Health, established on December 24, 1996, and listed on February 17, 2015, is primarily engaged in the research, production, and sales of medical devices, medical services, and large-volume intravenous products [1] - The company's revenue composition includes 52.07% from pharmaceutical manufacturing, 46.01% from medical services, 1.54% from pharmaceutical trading, and 0.38% from other sources [1] Industry Classification - Jimin Health is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables, with involvement in innovative drugs, cell therapy, in vitro diagnostics, antigen testing, and medical devices [2]

Core Viewpoint - Kelong Pharmaceutical's stock has experienced a decline of 2.00% on November 3, with a current price of 34.30 CNY per share and a total market capitalization of 54.813 billion CNY [1] Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion CNY, representing a year-on-year decrease of 20.92%. The net profit attributable to shareholders was 1.201 billion CNY, down 51.41% year-on-year [2] - The company has cumulatively distributed dividends of 6.898 billion CNY since its A-share listing, with 3.587 billion CNY distributed in the last three years [3] Stock Market Activity - Kelong Pharmaceutical's stock price has increased by 17.05% year-to-date, but has seen declines of 1.18% over the last five trading days, 6.73% over the last 20 days, and 7.41% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on April 30, where it recorded a net purchase of 31.8792 million CNY [1] Shareholder Information - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period. The average number of tradable shares per shareholder was 35,200, a decrease of 7.70% [2] - The top ten circulating shareholders include various funds, with notable reductions in holdings for several institutional investors [3]

Core Viewpoint - Kelong Pharmaceutical is a leading enterprise in the domestic large infusion industry, with strong R&D capabilities and a full industry chain advantage [1] Group 1: Business Performance - As of Q3 2025, Kelong Pharmaceutical reported revenue of 13.277 billion, ranking 5th in the industry, exceeding the industry average by 2.8 billion and the median by 0.838 billion, but lower than the top two competitors [2] - The net profit for the same period was 1.245 billion, ranking 9th in the industry, above the industry average of 299 million and the median of 78.29 million, but below the top two competitors [2] Group 2: Financial Ratios - Kelong Pharmaceutical's debt-to-asset ratio was 28.63% in Q3 2025, down from 31.68% year-on-year and below the industry average of 35.26%, indicating good solvency [3] - The gross profit margin for the same period was 47.89%, down from 52.51% year-on-year and below the industry average of 57.17%, suggesting a need for improvement in profitability [3] Group 3: Executive Compensation - Chairman Liu Gexin's salary decreased from 6.9 million in 2023 to 5.6 million in 2024, a reduction of 1.3 million [4] - General Manager Liu Sicong's salary remained stable at 4.8 million in 2024 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 8.35% to 37,100, while the average number of shares held per shareholder decreased by 7.70% [5] Group 5: Future Outlook - Kelong Pharmaceutical's H1 2025 performance showed a decline, with revenue of 9.083 billion, down 23.2% year-on-year, and net profit of 1.001 billion, down 44.41% [6] - The company expects revenues for 2025-2027 to be 17.886 billion, 20.569 billion, and 22.626 billion, with respective year-on-year changes of -18.0%, +15.0%, and +10.0% [6] - Net profits for the same period are projected to be 2.022 billion, 2.801 billion, and 3.204 billion, with year-on-year changes of -31.1%, +38.5%, and +14.4% [6] Group 6: Innovation and R&D - Kelong Pharmaceutical's innovative drugs are showing rapid sales growth, with the newly approved product contributing to sales [6] - The company has over 30 items in its innovative R&D pipeline, primarily focused on cancer treatment [6][7]

Core Viewpoint - Jimin Health reported a significant decline in revenue and net profit for the first three quarters of 2025, indicating financial challenges for the company [1][2]. Financial Performance - The company's revenue for the first three quarters was 545 million yuan, a year-on-year decrease of 20.21% [1]. - The net profit attributable to shareholders was -77.15 million yuan, a year-on-year decline of 371.51% [1]. - The net profit excluding non-recurring items was -76.54 million yuan, down 385.10% year-on-year [1]. - Basic earnings per share were -0.15 yuan [1]. Profitability Metrics - The gross margin for the first three quarters was 36.11%, down 7.14 percentage points year-on-year [2]. - The net margin was -13.84%, a decrease of 18.73 percentage points compared to the same period last year [2]. - In Q3 2025, the gross margin was 34.54%, down 6.31 percentage points year-on-year and down 1.58 percentage points quarter-on-quarter [2]. - The net margin for Q3 was -14.39%, a decline of 15.47 percentage points year-on-year, but an increase of 6.12 percentage points from the previous quarter [2]. Expense Analysis - Total operating expenses for the period were 235 million yuan, a decrease of 19.34 million yuan year-on-year [2]. - The expense ratio was 43.20%, an increase of 5.90 percentage points compared to the same period last year [2]. - Sales expenses decreased by 16.70%, while management expenses decreased by 1.51% [2]. - Research and development expenses increased by 0.79%, and financial expenses rose by 19.00% [2]. Company Overview - Jimin Health, established on December 24, 1996, is located in Taizhou, Zhejiang Province, and was listed on February 17, 2015 [3]. - The company's main business includes the research, production, and sales of medical devices, medical services, and large-volume infusion products [3]. - The revenue composition is as follows: pharmaceutical manufacturing 52.07%, medical services 46.01%, pharmaceutical trade 1.54%, and others 0.38% [3]. - Jimin Health is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables [3].

Core Viewpoint - On October 23, 2023, Kelun Pharmaceutical experienced a decline of 3.04% in stock price, with a trading volume of 362 million yuan, indicating market volatility and investor sentiment towards the company [1]. Financing and Trading Activity - On the same day, Kelun Pharmaceutical had a financing buy-in amount of 47.32 million yuan and a financing repayment of 34.36 million yuan, resulting in a net financing buy of 12.96 million yuan. The total financing and securities balance reached 936 million yuan [1]. - The current financing balance of 933 million yuan represents 1.68% of the circulating market value, which is above the 60th percentile level over the past year, indicating a relatively high financing level [1]. - In terms of securities lending, 5,900 shares were repaid, and 10,200 shares were sold short, amounting to 355,000 yuan at the closing price. The remaining short-selling volume was 80,000 shares, with a balance of 2.784 million yuan, which is below the 50th percentile level over the past year, suggesting a lower level of short interest [1]. Company Financial Performance - As of June 30, 2025, Kelun Pharmaceutical reported a total revenue of 9.083 billion yuan for the first half of the year, reflecting a year-on-year decrease of 23.20%. The net profit attributable to shareholders was 1.001 billion yuan, down 44.41% compared to the previous year [2]. - Since its A-share listing, Kelun Pharmaceutical has distributed a total of 6.898 billion yuan in dividends, with 3.587 billion yuan distributed over the past three years [2]. Shareholder Structure - As of June 30, 2025, the number of shareholders for Kelun Pharmaceutical reached 34,200, an increase of 2.55% from the previous period. The average number of circulating shares per shareholder decreased by 2.49% to 38,138 shares [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A (003095) by 12.6942 million shares, while Hong Kong Central Clearing Limited reduced its holdings by 2.7086 million shares [3].